9 completed, 2 active not recruiting, 2 terminated, 1 enrolling by invitation. 5 Phase 4, 4 Not applicable, 2 Phase 2, 1 Phase 3.
Follow Buprenorphine: new trials by email Literature Review of Buprenorphine trials Research Report on Buprenorphine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Injectable Buprenorphine in Prison: A Preference Trial Brixadi (Injectable Buprenorphine), Sublocade - Opioid Use Disorder, Incarceration | Phase 4 | Recruiting | Lifespan | 60 | 2026-02-18 | 2026-05-15 |
| Peer Recovery Support for Opioid Use Disorder Treatment Retention Peer Support - Opioid Use Disorder, Peer Recovery Supporters | Not applicable | Enrolling by invitation | University of Pennsylvania | 15 | 2026-01-09 | 2026-06-02 |
| Comparative Efficacy of Buprenorphine Transdermal Patch Versus Tramadol in Postoperative Analgesia for Shoulder Arthroscopy Buprenorphine transdermal patch, Tramadol - Postoperative Pain, Shoulder Pain | Phase 4 | Active not recruiting | medina medical center | 70 | 2024-12-01 | 2024-12-20 |
| Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1 Methadone, Buprenorphine/naloxone, XR-Naltrexone - Opioid-use Disorder, HIV-1-infection | Phase 2 | Terminated | University of Pennsylvania | 78 | 2023-01-30 | 2026-04-07 |
| Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing Stigma-reduction training, Placebo - Opioid-Related Disorders, Buprenorphine | Not applicable | Active not recruiting | Ohio University | 400 | 2022-09-01 | 2025-05-29 |
| Addition of Buprenorphine to Paracervical Block for Pain Control During Osmotic Dilator Insertion Buprenorphine 0.15 MG, Lidocaine 1% Injectable Solution - Procedural Pain, Buprenorphine | Phase 4 | Completed | University of California, San Diego | 57 | 2020-05-28 | 2023-08-01 |
| Clinical Decision Support to Implement ED-initiated Buprenorphine for OUD Clinical Decision Support (CDS) - Clinical Decision Support, Buprenorphine | Not applicable | Completed | Yale University | 5047 | 2019-11-15 | 2022-06-28 |
| Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior Evaluate model of care for HCV-infected adults with on-going opioid misuse - HCV, Buprenorphine | Completed | University of Maryland, Baltimore | 198 | 2017-05-01 | 2026-05-04 | |
| Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis Outpatient parenteral antibiotic therapy - Endocarditis, Bacterial, Opioid-use Disorder | Not applicable | Completed | Laura Fanucchi | 20 | 2017-03-01 | 2019-01-23 |
| The Effects of Opioid Taper on Opioid-Induced Hyperalgesia Buprenorphine - Buprenorphine, Pain | Terminated | Georgetown University | 15 | 2017-01-01 | 2018-03-21 | |
| Buprenorphine Transdermal Patches in Arthroscopic Rotator Cuff Repair Buprenorphine, Placebo Patch, Multimodal Oral Scheme - Rotator Cuff Tear, Rotator Cuff Injury | Phase 2 / Phase 3 | Completed | Hospital Italiano de Buenos Aires | 50 | 2016-09-22 | 2021-04-08 |
| Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users Opioid-related Disorders, Buprenorphine | Completed | Albert Einstein College of Medicine | 40 | 2009-12-01 | 2019-04-10 | |
| Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED) buprenorphine - Buprenorphine, Naloxone | Completed | Indivior Inc. | 1307 | 2007-05-01 | 2023-03-20 | |
| Integrating Buprenorphine Into the SFGH AIDS Program Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting - HIV, Buprenorphine | Phase 4 | Completed | University of California, San Francisco | 37 | 2005-12-01 | 2011-09-12 |
| Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Services will be provided at one site, Services remain dispersed; i.e., not centralized to one-location or provider. - Buprenorphine, HIV | Phase 4 | Completed | Yale University | 60 | 2005-08-01 | 2015-07-24 |
Opioid-Related Disorders (11) · Substance-Related Disorders (2) · Acquired Immunodeficiency Syndrome (1) · Dilatation, Pathologic (1) · Endocarditis, Bacterial (1) · HIV Infections (1) · Inflammation (1) · Narcotic-Related Disorders (1) · Pain (1) · Pain, Postoperative (1) · Pain, Procedural (1) · Rotator Cuff Injuries (1) · Shoulder Pain (1) · Social Stigma (1)
Chemically-Induced Disorders (11) · Mental Disorders (11) · Narcotic-Related Disorders (10) · Substance-Related Disorders (9) · Pathological Conditions, Signs and Symptoms (4) · Infections (3) · Neurologic Manifestations (3) · Signs and Symptoms (3) · Blood-Borne Infections (2) · Communicable Diseases (2) · Genital Diseases (2) · Immune System Diseases (2) · Immunologic Deficiency Syndromes (2) · Lentivirus Infections (2) · Pain (2)
Buprenorphine (6) · Buprenorphine, Naloxone Drug Combination (3) · Tramadol (2) · Drugs, Generic (1) · Lidocaine (1) · Methadone (1) · Sublocade (1) · vivitrol (1)
University of Pennsylvania (2) · Yale University (2) · Albert Einstein College of Medicine (1) · Georgetown University (1) · Hospital Italiano de Buenos Aires (1) · Indivior Inc. (1) · Laura Fanucchi (1) · Lifespan (1) · Ohio University (1) · University of California, San Diego (1) · University of California, San Francisco (1) · University of Maryland, Baltimore (1) · medina medical center (1)
United States (12) · Argentina (1) · Saudi Arabia (1) · Vietnam (1)
Berkeley Franz, Ph.D. (1) · Edward Melnick, MD, MHS (1) · Elana Rosenthal, MD (1) · Frederick Altice, MD (1) · Julia Arnsten, M.D., M.P.H. (1) · Laura Fanucchi, MD (1) · Luis J Montaner, DVM, D.Phil (1) · Nicole Economou, MD (1) · Paula J Lum, MD, MPH (1) · Peggy Compton, RN, PhD (1) · Rebecca A Harris, MD (1) · Sharon Walsh, PhD (1) · Sheila K Mody, MD, MPH (1)
PMID 21317588, PMID 21317589, PMID 21317590, PMID 21317591, PMID 21317592, PMID 21317595, PMID 21317596, PMID 21317597, PMID 21317598, PMID 21317600, PMID 21317602, PMID 29141650, PMID 31152039, PMID 31342057, PMID 32009165, PMID 32309637, PMID 33631356, PMID 35760423, PMID 35785613, PMID 37948075, PMID 38243307, PMID 38980680, PMID 39702538, PMID 40645369, PMID 41287157, PMID 41879782
K23DA054157 (1), K23DA055695 (1), U01DA029580 (1), UG3DA047003 (1)